The biotech company Oshadi Drug Administration Ltd. reached Phase II clinical trials (NCT01973920) involving T1D patients and using its Oshadi-Icp formulation, which consisted of enteric capsules containing insulin, proinsulin, and C-peptide non-covalently associated with a silica nanoparticle core branched with polysaccharides and embedded within an oil phase [109]. The gene discussed is INS; the disease is type 1 diabetes mellitus.